Are SGLT-2 inhibitors safe in patients with peripheral artery disease?

In a patient-level pooled analysis of the DAPA-HF and DELIVER trials, PAD was reported in 809 of 11,005 patients (7.4%). While the rate of the primary outcome (worsening HF or CV death) was higher among PAD vs. nonPAD patients, the benefit of dapagliflozin on the primary outcome was consistent regardless of the presence of PAD. Dapagliflozin did not increase the risk of amputation.